IRadimed - IRMD Stock Forecast, Price & News

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for IRadimed in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IRMD shares.
View IRMD analyst ratings or view top-rated stocks.

1 brokerages have issued 12 month price objectives for IRadimed's stock. Their IRMD share price forecasts range from $42.00 to $42.00. On average, they predict the company's stock price to reach $42.00 in the next twelve months. This suggests a possible upside of 44.7% from the stock's current price.
View analysts price targets for IRMD or view top-rated stocks among Wall Street analysts.

IRadimed's stock was trading at $46.21 on January 1st, 2022. Since then, IRMD shares have decreased by 37.2% and is now trading at $29.02.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Friday, November 4th 2022.
View our IRMD earnings forecast.

IRadimed Co. (NASDAQ:IRMD) posted its earnings results on Friday, July, 29th. The medical equipment provider reported $0.26 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.20 by $0.06. The medical equipment provider had revenue of $12.72 million for the quarter, compared to analysts' expectations of $12.64 million. IRadimed had a net margin of 25.42% and a trailing twelve-month return on equity of 18.11%.

IRadimed declared a dividend on Monday, February 7th. Stockholders of record on Thursday, February 17th will be paid a dividend of $1.00 per share on Thursday, February 24th. The ex-dividend date is Wednesday, February 16th.
Read our dividend analysis for IRMD.

IRadimed issued an update on its third quarter 2022 earnings guidance on Friday, August, 5th. The company provided EPS guidance of $0.22-$0.25 for the period, compared to the consensus earnings per share estimate of $0.25. The company issued revenue guidance of $13.10 million-$13.30 million, compared to the consensus revenue estimate of $13.07 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other IRadimed investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Alphabet (GOOG), Mastercard (MA), Micron Technology (MU), PayPal (PYPL), CRISPR Therapeutics (CRSP), IntriCon (IIN), QUALCOMM (QCOM) and Twitter (TWTR).

IRadimed trades on the NASDAQ under the ticker symbol "IRMD."

Shares of IRMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of IRMD stock can currently be purchased for approximately $29.02.

IRadimed (NASDAQ:IRMD) has a market capitalization of $364.49 million and generates $41.81 million in revenue each year. The medical equipment provider earns $9.32 million in net income (profit) each year or $0.97 on an earnings per share basis.

The company employs 110 workers across the globe.

IRadimed's mailing address is 1025 Willa Springs Dr., Winter Springs FL, 32708. The official website for the company is www.iradimed.com. The medical equipment provider can be reached via phone at (407) 677-8022, via email at investorrelations@iradimed.com, or via fax at 407-677-5037.